NASDAQ NMS - GLOBAL MARKET · AVTX
-1.10% · -$0.1500 · Vol 990.4K
After hours · updated 16:45:23 ET
Avalo Therapeutics Inc

Avalo Therapeutics Inc

Biotechnology
$13.43
Card
Relationship Map

Follow $AVTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $AVTX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
AVTX
Avalo Therapeutics Inc
Thu Oct 8 · session closed · Markets closed · resumes Fri 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · session closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AVTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AVTX catalysts
About Avalo Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
33
Country
US

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$13.45
Day high
$13.60
Day low
$12.77
Previous close
$13.58
52W high
$22.87
-41.28% from high
52W low
$12.74
7% of range
Market cap
$728.3M
EPS
$-5.9200
Beta
0.30
Shares out
53.6M
Volume
990.4K
0.92× rel vol
Avg volume
1.1M
VWAP
$13.33
Price history computed in-house
1W
-10.17%
1M
-31.86%
3M
-30.09%
1Y
-5.56%
YTD
-26.05%
SMA 50 $17.73 · below
SMA 200 $16.63 · below
52W position 7%

AVTX overview

Veridion Score
38
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AVTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AVTX Form 4 filings
Public disclosures

Congress activity in AVTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

AVTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVTX in this window.
Lobbying spend

AVTX lobbying filings, year to date.

Registered lobbying filings matched to Avalo Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AVTX in this window.
Loading news for AVTX
Analyst ratings
Sovereign unlock shows live analyst consensus for AVTX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.